Cure Systems LLC

Cure Systems develops a gene transfer platform technology that enables the delivery and sustained expression of antibody therapeutics from a single administration, with applications in vaccine development and treatment of infectious diseases, cancer, autoimmunity, and other conditions. The company was founded in 2020 and has completed Phase I clinical trials demonstrating durable antibody expression in humans over multiple years.